Metabolic dysfunction-associated fatty liver disease (MAFLD) is a modern, more inclusive, and precise nomenclature replacing non-alcoholic fatty liver disease (NAFLD). MAFLD is a multisystemic disease characterized by liver steatosis accompanied by overweight and obesity, type 2 diabetes mellitus, or other forms of metabolic dysregulation. The rising incidence of MAFLD has made it one of the most prevalent liver diseases worldwide. Although the global incidence of fatty liver and associated metabolic dysfunctions is soaring, it is noteworthy that this condition can, to some extent, be prevented through dietary interventions and functional compounds. In this context, experimental animal models offer excellent opportunities to deepen our understanding of the mechanisms of action of functional compounds in preventing MAFLD through nutriomic studies. Additionally, human studies are invaluable for translating these findings into clinical practice and understanding the disease in a real-world context. Given the redefinition and expansion of NAFLD to MAFLD, numerous questions have surfaced regarding the underlying mechanisms involved in the prevention of this disease. Thus, the aim of this proposal is to provide comprehensive nutriomic insights into the effects of foods and functional compounds on the prevention of MAFLD, utilizing both experimental animal models and human studies.
This research topic aims to elucidate the nutriomic effects of foods and functional compounds on the prevention of MAFLD. Specifically, it seeks to investigate the metabolic pathways, nutrigenomic effects, and synergistic actions of bioactive compounds in both animal models and human studies. By addressing these questions, the research aims to advance our understanding of how dietary interventions can mitigate the risk of MAFLD, ultimately contributing to more effective prevention strategies and better health outcomes.
To gather further insights into the nutriomic analysis of food and functional compounds for MAFLD prevention, we welcome articles addressing, but not limited to, the following themes:
• Nutriomic studies investigating the metabolic pathways involved in the protective effects of functional foods in animal models and human studies of MAFLD
• Nutrigenomic effects of functional foods or compounds on MAFLD biomarkers in both animal models and human participants
• Metabolomic and transcriptomic studies exploring the synergistic effects of bioactive compounds in preventing liver steatosis and other MAFLD-related alterations
• Research identifying the response of genetic variants to functional compounds in the prevention of MAFLD
• Studies on epigenome modulation leading to the mitigation of MAFLD in experimental models and human populations
• Comparative analysis of experimental animal models and human studies used to investigate the nutriomic effects of functional compounds on MAFLD prevention
• Foodomic analysis and dietary strategies for preventing MAFLD in both experimental models and clinical settings
• Investigations into the role of functional foods and gut microbiota in the prevention of MAFLD in animal models and human subjects
• Application of new technologies to study the mechanisms involved in the prevention of MAFLD by food compounds in animal models and human studies
Metabolic dysfunction-associated fatty liver disease (MAFLD) is a modern, more inclusive, and precise nomenclature replacing non-alcoholic fatty liver disease (NAFLD). MAFLD is a multisystemic disease characterized by liver steatosis accompanied by overweight and obesity, type 2 diabetes mellitus, or other forms of metabolic dysregulation. The rising incidence of MAFLD has made it one of the most prevalent liver diseases worldwide. Although the global incidence of fatty liver and associated metabolic dysfunctions is soaring, it is noteworthy that this condition can, to some extent, be prevented through dietary interventions and functional compounds. In this context, experimental animal models offer excellent opportunities to deepen our understanding of the mechanisms of action of functional compounds in preventing MAFLD through nutriomic studies. Additionally, human studies are invaluable for translating these findings into clinical practice and understanding the disease in a real-world context. Given the redefinition and expansion of NAFLD to MAFLD, numerous questions have surfaced regarding the underlying mechanisms involved in the prevention of this disease. Thus, the aim of this proposal is to provide comprehensive nutriomic insights into the effects of foods and functional compounds on the prevention of MAFLD, utilizing both experimental animal models and human studies.
This research topic aims to elucidate the nutriomic effects of foods and functional compounds on the prevention of MAFLD. Specifically, it seeks to investigate the metabolic pathways, nutrigenomic effects, and synergistic actions of bioactive compounds in both animal models and human studies. By addressing these questions, the research aims to advance our understanding of how dietary interventions can mitigate the risk of MAFLD, ultimately contributing to more effective prevention strategies and better health outcomes.
To gather further insights into the nutriomic analysis of food and functional compounds for MAFLD prevention, we welcome articles addressing, but not limited to, the following themes:
• Nutriomic studies investigating the metabolic pathways involved in the protective effects of functional foods in animal models and human studies of MAFLD
• Nutrigenomic effects of functional foods or compounds on MAFLD biomarkers in both animal models and human participants
• Metabolomic and transcriptomic studies exploring the synergistic effects of bioactive compounds in preventing liver steatosis and other MAFLD-related alterations
• Research identifying the response of genetic variants to functional compounds in the prevention of MAFLD
• Studies on epigenome modulation leading to the mitigation of MAFLD in experimental models and human populations
• Comparative analysis of experimental animal models and human studies used to investigate the nutriomic effects of functional compounds on MAFLD prevention
• Foodomic analysis and dietary strategies for preventing MAFLD in both experimental models and clinical settings
• Investigations into the role of functional foods and gut microbiota in the prevention of MAFLD in animal models and human subjects
• Application of new technologies to study the mechanisms involved in the prevention of MAFLD by food compounds in animal models and human studies